Loading viewer...
investor_presentation
Format: PDF investor_presentation
ProMIS Neurosciences presents PMN310, a potential Alzheimer's treatment targeting toxic amyloid-beta oligomers. Phase 1a data shows good tolerability with appropriate CSF levels supporting potential for monthly dosing and subcutaneous administration. The program aims to improve potency, safety, and compliance over existing therapies with no expected ARIA liability.
investor_presentation
23 Pages
Ndiva Wellness Inc.
Seacoast Banking Drummond Acquisition 2022
investor_presentationinvestor_presentation
18 Pages
Seacoast Banking Corporation of Florida